# A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

> **NCT06175494** · PHASE3 · UNKNOWN · sponsor: **WestVac Biopharma Co., Ltd.** · enrollment: 4800 (estimated)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
- **BIOLOGICAL:** Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06175494
- **Lead sponsor:** WestVac Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-19
- **Primary completion:** 2024-07-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 4800 (ESTIMATED)
- **Last updated:** 2024-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06175494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06175494, "A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06175494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*